MCID: SPN225
MIFTS: 71

Spondyloarthropathy 1

Categories: Genetic diseases, Rare diseases, Bone diseases

Aliases & Classifications for Spondyloarthropathy 1

MalaCards integrated aliases for Spondyloarthropathy 1:

Name: Spondyloarthropathy 1 53 71 37
Ankylosing Spondylitis 53 37 12 72 49 24 71 36 28 40 14 69
Marie-Strumpell Spondylitis 53 49 71
Bechterew Syndrome 53 49 71
Spondyloarthropathy, Susceptibility to, 1 53 13
Spondylarthritis Ankylopoietica 24 71
Spondylitis, Ankylosing 24 41
Reiter Syndrome 71 69
Spda1 53 71
Ankylosing Spondylitis, Susceptibility to 53
Spondyloarthritis Ankylopoietica 24
Ankylosing Spondyloarthritis 49
Ankylosing Spondylarthritis 71
Spondylitis Ankylopoietica 24
Marie-Struempell Disease 24
Marie-Strumpell Disease 12
Rheumatoid Spondylitis 71
Spondylitis Ankylosans 71
Spondylitis Ankylosing 51
Spondylarthropathies 69
Arthritis, Psoriatic 69
Psoriatic Arthritis 71
Bekhterev's Disease 12
Arthritis, Reactive 69
Reactive Arthritis 71
Bekhterev Syndrome 12
Bechterew Disease 24
As 24

Characteristics:

OMIM:

53
Inheritance:
multifactorial

Miscellaneous:
overall prevalence is between 0.5 and 14 per 100,000 people per year
genetic heterogeneity (see spondyloarthropathy, susceptibility to, 2 )
spondyloarthropathy includes a spectrum of related disorders, including, 1 - ankylosing spondylitis (as), 2 - a subset of psoriatic arthritis (psa), 3 - reactive arthritis (rea), 4 - arthritis associated with inflammatory bowel disease (aibd), 5 - undifferentiated spondyloarthropathy (uspa)


HPO:

31
spondyloarthropathy 1:
Inheritance heterogeneous multifactorial inheritance


Classifications:



Summaries for Spondyloarthropathy 1

MedlinePlus : 40 Ankylosing spondylitis is a type of arthritis of the spine. It causes inflammation between your vertebrae, which are the bones that make up your spine, and in the joints between your spine and pelvis. In some people, it can affect other joints. AS is more common and more severe in men. It often runs in families. The cause is unknown, but it is likely that both genes and factors in the environment play a role. Early symptoms of AS include back pain and stiffness. These problems often start in late adolescence or early adulthood. Over time, AS can fuse your vertebrae together, limiting movement. Some people have symptoms that come and go. Others have severe, ongoing pain. A diagnosis of AS is based on your medical history and a physical examination. You may also have imaging or blood tests. AS has no cure, but medicines can relieve symptoms and may keep the disease from getting worse. Eating a healthy diet, not smoking, and exercising can also help. In rare cases, you may need surgery to straighten the spine. NIH: National Institute of Arthritis and Musculoskeletal and Skin Disease

MalaCards based summary : Spondyloarthropathy 1, also known as ankylosing spondylitis, is related to aortic valve disease 2 and spondylitis, and has symptoms including pain, stiffness in the spine and stiffness in the neck. An important gene associated with Spondyloarthropathy 1 is HLA-B (Major Histocompatibility Complex, Class I, B), and among its related pathways/superpathways are Antigen processing and presentation and Antirheumatics - DMARDs and biological agents. The drugs Celecoxib and Etanercept have been mentioned in the context of this disorder. Affiliated tissues include Placenta and Umbilical Cord, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

OMIM : 53 Spondyloarthropathy (SpA), one of the commonest chronic rheumatic diseases, includes a spectrum of related disorders comprising the prototype ankylosing spondylitis (AS), a subset of psoriatic arthritis (PsA), reactive arthritis (ReA), arthritis associated with inflammatory bowel disease, and undifferentiated spondyloarthropathy (Miceli-Richard et al., 2004). These phenotypes are difficult to differentiate because they may occur simultaneously or sequentially in the same patient. Studies have suggested that a predominant shared component, including HLA-B27, predisposes to all phenotypic subsets, and that these subsets should be considered as various phenotypic expressions of the same disease (Said-Nahal et al., 2000, Said-Nahal et al., 2001). Braun and Sieper (2007) provided a detailed review of ankylosing spondylitis, including clinical features, pathogenesis, and management. (106300)

UniProtKB/Swiss-Prot : 71 Spondyloarthropathy 1: A chronic rheumatic disease with multifactorial inheritance. It includes a spectrum of related disorders comprising ankylosing spondylitis, a subset of psoriatic arthritis, reactive arthritis (e.g. Reiter syndrome), arthritis associated with inflammatory bowel disease and undifferentiated spondyloarthropathy. These disorders may occur simultaneously or sequentially in the same patient, probably representing various phenotypic expressions of the same disease. Ankylosing spondylitis is the form of rheumatoid arthritis affecting the spine and is considered the prototype of seronegative spondyloarthropathies. It produces pain and stiffness as a result of inflammation of the sacroiliac, intervertebral, and costovertebral joints.

NIH Rare Diseases : 49 Ankylosing spondylitis (AS) is a type of chronic, inflammatory arthritis that mainly affects the spine. It usually begins with inflammation of the joints between the pelvic bones and spine, gradually spreading to the joints between the vertebrae. Signs and symptoms usually begin in adolescence or early adulthood and may include back pain and stiffness. Back movement gradually becomes more limited as the vertebrae fuse together. The condition may also affect the shoulders; ribs; hips; knees; and feet; as well as the eyes; bowel; and very rarely, the heart and lungs. AS is likely caused by a combination of genetic and environmental factors; variations in several genes are thought to affect the risk to develop AS. In most cases, treatment involves exercise and medications to relieve pain and inflammation. Last updated: 2/9/2015

Genetics Home Reference : 24 Ankylosing spondylitis is a form of ongoing joint inflammation (chronic inflammatory arthritis) that primarily affects the spine. This condition is characterized by back pain and stiffness that typically appear in adolescence or early adulthood. Over time, back movement gradually becomes limited as the bones of the spine (vertebrae) fuse together. This progressive bony fusion is called ankylosis.

Disease Ontology : 12 A bone inflammation disease that results_in inflammation in the joints of the spine and pelvis. The disease has symptom pain, has symptom stiffness in the spine, has symptom stiffness in the neck, has symptom stiffness in the hips, has symptom stiffness in the jaw and has symptom stiffness in the rib cage.

Wikipedia : 72 Ankylosing spondylitis (AS) is a type of arthritis in which there is long term inflammation of the... more...

Related Diseases for Spondyloarthropathy 1

Diseases in the Spondyloarthropathy family:

Spondyloarthropathy 1 Spondyloarthropathy 2
Spondyloarthropathy 3 Juvenile Spondyloarthropathy

Diseases related to Spondyloarthropathy 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 423)
# Related Disease Score Top Affiliating Genes
1 aortic valve disease 2 32.0 CRP TNFRSF11B TNFSF11
2 spondylitis 31.4 CD40LG CRP HLA-B IL17A NOD2 TNF
3 uveitis 31.1 HLA-B IL17A NOD2 TNF
4 pustulosis of palm and sole 30.9 MRAP TNF TNFRSF1B
5 crohn's disease 30.7 CRP NOD2 TNF TNFRSF1B
6 ankylosis 30.6 ANKH BGLAP TNFRSF11B
7 reactive arthritis 30.6 CD79A CRP HLA-B IL17A TNF
8 mycobacterium tuberculosis 1 30.6 IL17A TNF TNFRSF1B
9 iritis 30.5 CD40LG HLA-B MRAP TNFRSF1B
10 aortitis 30.5 CRP MRAP
11 hypopyon 30.5 HLA-B MRAP
12 subacute bacterial endocarditis 30.4 CD40LG CD79A
13 vasculitis 30.3 CD40LG CD79A CRP TNF TNFRSF1B
14 purpura 30.2 CD40LG CD79A CRP TNF
15 granulomatous dermatitis 30.2 NOD2 TNF TNFRSF1B
16 meningitis 30.2 CD40LG CRP TNF
17 erythema elevatum diutinum 30.1 CD40LG CD79A
18 axial osteomalacia 30.1 BGLAP MRAP
19 iridocyclitis 30.1 CD40LG HLA-B MRAP
20 hidradenitis suppurativa 30.1 IL17A NOD2 TNF
21 hidradenitis 30.1 IL17A NOD2 TNF
22 chorioretinitis 30.0 CD40LG CD79A MRAP
23 brucellosis 30.0 CD40LG CRP IL1RN TNF
24 chlamydia 30.0 CD40LG CD79A CRP TNF
25 spondyloarthropathy 29.8 HLA-B IL17A MMP3 MRAP TNF TNFSF11
26 multicentric reticulohistiocytosis 29.7 TNFRSF11B TNFSF11
27 adult-onset still's disease 29.7 CRP IL1RN TNF
28 osteoarthritis 29.6 CRP MMP3 TNF TNFRSF11B TNFSF11
29 demyelinating disease 29.6 CD40LG IL17A TNF TNFRSF1A
30 temporal arteritis 29.5 CD40LG CRP IL1RN
31 arthropathy 29.5 ANKH CRP TNF TNFRSF11B TNFSF11
32 rheumatic disease 29.5 CD40LG CRP HLA-B TNF TNFRSF11B
33 aggressive periodontitis 29.2 IL1RN TNF TNFSF11
34 systemic lupus erythematosus 29.2 CD40LG CD79A CRP IL17A TNF TNFRSF1A
35 familial mediterranean fever 29.2 CRP IL1RN NOD2 TNF TNFRSF1A
36 arthritis 29.2 ANKH IL17A IL1RN MMP3 NOD2 TNF
37 osteoporosis 28.6 BGLAP CRP IL1RN TNF TNFRSF11B TNFSF11
38 autoimmune disease 28.5 CD40LG CD79A HLA-B IL17A IL1RN TNF
39 periodontitis 28.4 BGLAP CRP IL17A MMP3 TNF TNFRSF11B
40 psoriatic arthritis 28.4 CRP HLA-B IL17A MMP3 NOD2 TNF
41 synovitis 28.4 CRP IL1RN MMP3 TNF TNFRSF11B TNFSF11
42 inflammatory bowel disease 27.5 BGLAP CD79A CRP HLA-B IL17A IL1RN
43 rheumatoid arthritis 27.4 CD40LG CD79A CRP HLA-B IL17A IL1RN
44 bone inflammation disease 26.4 CD40LG CD79A CRP IL17A IL1RN MMP3
45 smoking as a quantitative trait locus 3 12.1
46 smoking as a quantitative trait locus 1 11.9
47 smoking as a quantitative trait locus 2 11.9
48 stature as a quantitative trait 11.9
49 angelman syndrome 11.7
50 spinal disease 11.5

Comorbidity relations with Spondyloarthropathy 1 via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Hypertension, Essential Osteoporosis
Rheumatoid Arthritis

Graphical network of the top 20 diseases related to Spondyloarthropathy 1:



Diseases related to Spondyloarthropathy 1

Symptoms & Phenotypes for Spondyloarthropathy 1

Symptoms via clinical synopsis from OMIM:

53
Skin Nails Hair Skin:
psoriasis

Cardiovascular Heart:
aortic insufficiency
aortitis
cardiac conduction abnormalities

Skeletal Spine:
accentuated kyphosis
back stiffness
nocturnal back pain
ankylosing spondylitis
sacroiliitis
more
Skeletal Limbs:
peripheral arthritis (oligoarticular or polyarticular)
peripheral enthesitis

Head And Neck Eyes:
anterior uveitis

Abdomen Gastroin testinal:
inflammatory bowel disease (crohns disease and ulcerative colitis)

Skeletal Pelvis:
arthritis (hip)

Laboratory Abnormalities:
hla-b27 haplotype association (95% patients)
rheumatoid factor negative


Clinical features from OMIM:

106300

Symptoms:

12
  • pain
  • stiffness in the spine
  • stiffness in the neck
  • stiffness in the hips
  • stiffness in the jaw
  • stiffness in the rib cage

Human phenotypes related to Spondyloarthropathy 1:

31 (show all 11)
# Description HPO Frequency HPO Source Accession
1 back pain 31 HP:0003418
2 kyphosis 31 HP:0002808
3 arthritis 31 HP:0001369
4 arrhythmia 31 HP:0011675
5 inflammation of the large intestine 31 HP:0002037
6 aortic regurgitation 31 HP:0001659
7 enthesitis 31 HP:0100686
8 anterior uveitis 31 HP:0012122
9 hip osteoarthritis 31 HP:0008843
10 sacroiliac arthritis 31 HP:0012317
11 psoriasiform dermatitis 31 HP:0003765

UMLS symptoms related to Spondyloarthropathy 1:


sciatica, muscle cramp, back pain

GenomeRNAi Phenotypes related to Spondyloarthropathy 1 according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 IL17A NOD2 TNF TNFRSF11B TNFRSF1A TNFRSF1B
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 IL17A NOD2 TNF TNFRSF11B TNFRSF1A TNFRSF1B
3 Increased shRNA abundance GR00327-A 9.35 HLA-B IL1RN MMP3 BGLAP CD79A

MGI Mouse Phenotypes related to Spondyloarthropathy 1:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.07 MMP3 TNFSF11 NOD2 ANKH TAPBP TNF
2 homeostasis/metabolism MP:0005376 9.93 MMP3 TNFSF11 NOD2 ANKH TNF CD40LG
3 craniofacial MP:0005382 9.87 TNFSF11 ANKH TNF TNFRSF11B TNFRSF1A IL17A
4 immune system MP:0005387 9.8 MMP3 TNFSF11 NOD2 ANKH TAPBP TNF
5 skeleton MP:0005390 9.36 MMP3 TNFSF11 NOD2 ANKH TNF CD40LG

Drugs & Therapeutics for Spondyloarthropathy 1

Drugs for Spondyloarthropathy 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 136)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 169590-42-5 2662
2
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 185243-69-0
3
Sulfasalazine Approved Phase 4,Phase 2,Phase 3,Phase 1 599-79-1 5359476 5353980
4
Adalimumab Approved Phase 4,Phase 2,Phase 3,Not Applicable 331731-18-1 16219006
5
Certolizumab pegol Approved Phase 4,Phase 3,Phase 2,Phase 1 428863-50-7
6
Infliximab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 170277-31-3
7
Pamidronate Approved Phase 4,Phase 1,Phase 2 40391-99-9 4674
8
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 9579578 4594
9
Naproxen Approved, Vet_approved Phase 4,Phase 3 22204-53-1 156391 1302
10
Methotrexate Approved Phase 4,Phase 2,Phase 3,Phase 1 1959-05-2, 59-05-2 126941
11
Diclofenac Approved, Vet_approved Phase 4,Phase 3 15307-86-5 3033
12
Alendronate Approved Phase 4 121268-17-5, 66376-36-1 2088
13
Aceclofenac Approved, Investigational Phase 4 89796-99-6
14
Acetaminophen Approved Phase 4 103-90-2 1983
15
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
16
Hydroxychloroquine Approved Phase 4,Phase 3 118-42-3 3652
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 59-30-3 6037
18
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2 58-05-9 143 6006
19 Analgesics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
20 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
21 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Not Applicable
22 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
23 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
24 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
25 Cyclooxygenase 2 Inhibitors Phase 4,Phase 3,Phase 1,Not Applicable
26 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
28 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
30 Dermatologic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
31 Natriuretic Agents Phase 4
32 Natriuretic Peptide, Brain Phase 4
33 Antacids Phase 4,Phase 3
34 Anti-Ulcer Agents Phase 4,Phase 3
35 Proton pump inhibitors Phase 4,Phase 3
36 Antimetabolites Phase 4,Phase 3,Phase 2,Not Applicable
37 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2
38 Folic Acid Antagonists Phase 4,Phase 3,Phase 2
39 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2
40 Vaccines Phase 4,Phase 2
41 Vitamin B Complex Phase 4,Phase 3,Phase 2
42 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Bone Density Conservation Agents Phase 4,Phase 1
46 Anticholesteremic Agents Phase 4,Not Applicable
47 Cholestyramine Resin Phase 4
48 Hypolipidemic Agents Phase 4,Not Applicable
49 Lipid Regulating Agents Phase 4,Not Applicable
50 Analgesics, Opioid Phase 4

Interventional clinical trials:

(show top 50) (show all 347)

# Name Status NCT ID Phase Drugs
1 Dose Reduction of Etanercept in Patients With Ankylosing Spondylitis Unknown status NCT02638896 Phase 4 etanercept (Half-Dose);etanercept (Full-Dose);Sulfasalazine;Celecoxib
2 Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study Unknown status NCT02489760 Phase 4
3 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4 Etanercept;Adalimumab;Certolizumab;Infliximab
4 Heart Function in Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker Unknown status NCT01072058 Phase 4 TNF blockers (infliximab, adalimumab, etanercept)
5 Combined Treatment With TNF Inhibitor and Pamidronate in AS Patients: Effect on the Radiographic Progression Unknown status NCT02313727 Phase 4 Pamidronate
6 Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis Unknown status NCT02355236 Phase 4 Naproxen/Esomeprazol 500/20mg;Celecoxib 200mg;Naxozol-Placebo;Comparator-Placebo
7 Study Evaluating Etanercept and Sulphasalazine in Ankylosing Spondylitis Completed NCT00247962 Phase 4 etanercept;sulphasalazine (SSZ)
8 Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS) Completed NCT01895764 Phase 4 Adalimumab;Methotrexate
9 Study Evaluating Etanercept in Subjects With Ankylosing Spondylitis in Spain Completed NCT00873730 Phase 4 etanercept;etanercept/placebo
10 Study Evaluating Etanercept for the Treatment of Active, Severe, and Advanced Axial Ankylosing Spondylitis Completed NCT00420238 Phase 4 Etanercept (Enbrel)
11 A Study Of Celecoxib Versus Diclofenac In Patients With Ankylosing Spondylitis Completed NCT02528201 Phase 4 Celecoxib 200 milligrams;Celecoxib 400 milligrams;diclofenac 50 milligrams
12 Work Productivity in Active Ankylosing Spondylitis (AS) Patients Treated With Enbrel. Completed NCT01421303 Phase 4 Enbrel
13 Study Evaluating Etanercept in Patients With Ankylosing Spondylitis Completed NCT00458185 Phase 4 etanercept
14 The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012) Completed NCT01668004 Phase 4
15 An Open-Label Multicentre Long-Term Extension Study of Etanercept for Ankylosing Spondylitis Completed NCT00444340 Phase 4 Enbrel (Etanercept)
16 Study Investigating Enbrel Treatment for Ankylosing Spondylitis Completed NCT00195416 Phase 4 Etanercept
17 Extension Study Evaluating Etanercept in Ankylosing Spondylitis Completed NCT00410046 Phase 4 Enbrel (etanercept)
18 Study Evaluating The Use Of Etanercept In Patients With Ankylosing Spondylitis Completed NCT00544557 Phase 4 Etanercept
19 Infliximab and Methotrexate in Ankylosing Spondylitis Completed NCT00507403 Phase 4 infliximab
20 Efficacy and Safety of Kunxian Capsule in Treatment Patients With Early Ankylosing Spondylitis Completed NCT00953979 Phase 4 kunxian capsule
21 Treatment With Alendronate in Patients With Ankylosing Spondylitis (AS) Completed NCT01104987 Phase 4 alendronate
22 Effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) on RAdiographic Damage in Ankylosing Spondylitis Completed NCT00715091 Phase 4 diclophenac;diclophenac
23 Effect of Anti-TNF (Alpha) Treatment on Vascular Stiffness in Ankylosing Spondylitis (AS) Completed NCT01212653 Phase 4 Simponi
24 Relapse of Ankylosing Spondylitis Patients Withdrawal Etanercept After Clinical Remission: a Following-up Study Completed NCT02915354 Phase 4 Etanercept
25 Combination Methotrexate and Infliximab Completed NCT00432432 Phase 4 Infliximab and MTX
26 Total Glucosides Paeony Capsules in Maintaining Clinical Remission in Patients With Ankylosing Spondylitis Which Achieve Clinical Remission After Anti-TNF Therapy Completed NCT01517620 Phase 4 Total Glucosides Paeony Capsules
27 Tramadol/Acetaminophen(Ultracet) AS add-on Therapy in the Treatment of Patients With Ankylosing Spondylitis Completed NCT00647517 Phase 4 Ultracet
28 An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Participants Completed NCT00760669 Phase 4 Infliximab; observational study;Methotrexate; observational study
29 Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment (Study P04465)(COMPLETED) Completed NCT00778869 Phase 4
30 Efficacy and Safety Study of Infliximab (Remicade) to Treat Early Ankylosing Spondylitis Completed NCT00936143 Phase 4 infliximab
31 A Study of the Efficacy and Tolerance of Remicade in the Treatment of Active Ankylosing Spondylitis (Study P04042)(COMPLETED) Completed NCT00779012 Phase 4
32 Growth Factor Concentration to Predict an Ankylosing Spondylitis Patient's Response to Infliximab (Study P04041)(COMPLETED) Completed NCT00779935 Phase 4
33 Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing Completed NCT01174186 Phase 4 Adalimumab
34 Post Marketing Surveillance of Remicade Completed NCT00724529 Phase 4
35 A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment Completed NCT02897115 Phase 4
36 Evaluation of a Protocol for Dose Reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF Completed NCT01604629 Phase 4 Reduced doses of anti-TNF;Stable doses of anti-TNF
37 Adalimumab in Axial Spondyloarthritis (ASIM) - MRI and Biomarkers in Patients With Spondyloarthritis Completed NCT01029847 Phase 4 Adalimumab;Placebo
38 Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy: a 48-week Trial Completed NCT01718951 Phase 4 golimumab;Pamidronate
39 TNFalfa Blocking Treatment of Spondylarthropathies Completed NCT00133315 Phase 4 Infliximab;Etanercept;Adalimumab
40 Study Comparing the Efficacy and Safety of Continuing Versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects With Non-Radiographic Axial Spondyloarthritis Completed NCT01808118 Phase 4
41 A Study to Evaluate the NSAIDS Sparing Effect of Etanercept in Subjects With Axial Spondyloarthritis Completed NCT01298531 Phase 4 etanercept;etanercept;placebo
42 NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in Ankylosing Spondylitis Recruiting NCT02758782 Phase 4 Celecoxib
43 A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab (AIN457) to Examine the Clinical Efficacy and the Nonsteroidal Anti-inflammatory Drug (NSAID)-Sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylit Recruiting NCT02763046 Phase 4 AIN457/Secukinumab Placebo
44 Biomarkers Identification of Anti-tumor Necrosis Factor (TNF) α Agent's Efficacy in Ankylosing Spondylitis Patients Recruiting NCT02492217 Phase 4 Adalimumab
45 Sequential Application of Yisaipu® and DMARDs in Treating Mild-to-Moderate AS Recruiting NCT03411798 Phase 4 Yisaipu®
46 Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis Recruiting NCT03473665 Phase 4 Indomethacin;Diclofenac;Meloxicam;Celecoxib
47 Adalimumab in Alleviating Inflammation in Patients With Axial Spondyloarthritis Recruiting NCT02634541 Phase 4 Adalimumab
48 Etanercept Withdrawal And Retreament Study In Subjects With Nr-ax SpA Recruiting NCT02509026 Phase 4
49 Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (MK-8259-038) Recruiting NCT03253796 Phase 4
50 Delaying Ossification and Improving Inflammation of Celebrex Plus/or Enbrel Treatment on Active Ankylosing Spondylitis Active, not recruiting NCT01934933 Phase 4 celebrex;Enbrel;Enbrel plus Celebrex

Search NIH Clinical Center for Spondyloarthropathy 1

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Spondyloarthropathy 1 cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Spondyloarthropathy 1:
Umbilical cord-derived mesenchymal stem cells to treat ankylosing spondylitis
Embryonic/Adult Cultured Cells Related to Spondyloarthropathy 1:
Umbilical cord-derived mesenchymal stem cells (family)
Placenta-derived mesenchymal stem cells (family)

Cochrane evidence based reviews: spondylitis, ankylosing

Genetic Tests for Spondyloarthropathy 1

Genetic tests related to Spondyloarthropathy 1:

# Genetic test Affiliating Genes
1 Ankylosing Spondylitis 28 HLA-B

Anatomical Context for Spondyloarthropathy 1

MalaCards organs/tissues related to Spondyloarthropathy 1:

38
Bone, Eye, Lung, Skin, Heart, Testes
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Spondyloarthropathy 1:
# Tissue Anatomical CompartmentCell Relevance
1 Placenta Chorionic Villus Chorionic Mesenchymal Stromal Cells Potential therapeutic candidate
2 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate
3 Blood Cord Blood Mesenchymal Stem Cells Potential therapeutic candidate

Publications for Spondyloarthropathy 1

Articles related to Spondyloarthropathy 1:

(show top 50) (show all 1584)
# Title Authors Year
1
Bone formation in ankylosing spondylitis during anti-tumour necrosis factor therapy imaged by 18F-fluoride positron emission tomography. ( 29415219 )
2018
2
The association of HLA-B27 and Klebsiella pneumoniae in ankylosing spondylitis: A systematic review. ( 29438717 )
2018
3
MMP-2 silencing reduces the osteogenic transformation of fibroblasts by inhibiting the activation of the BMP/Smad pathway in ankylosing spondylitis. ( 29435070 )
2018
4
Screening for key genes and transcription factors in ankylosing spondylitis by RNA-Seq. ( 29434723 )
2018
5
Stability of fatigue, pain, patient global assessment and the Bath Ankylosing Spondylitis Functional Index (BASFI) in spondyloarthropathy patients with stable disease according to the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). ( 29299630 )
2018
6
Assessment of effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting for treatment of patients with active rheumatoid arthritis or ankylosing spondylitis. ( 29439591 )
2018
7
Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort. ( 29449504 )
2018
8
Ankylosing Spondylitis Treatment after First Anti-TNF Drug Failure. ( 29431309 )
2018
9
Recurrent anterior uveitis and subsequent incidence of ankylosing spondylitis: a nationwide cohort study from 2002 to 2013. ( 29415753 )
2018
10
Using Self-Reported Patient Experiences to Understand Patient Burden: Learnings from Digital Patient Communities in Ankylosing Spondylitis. ( 29450863 )
2018
11
Safety and Efficacy of Golimumab Administered Intravenously in Adults with Ankylosing Spondylitis: Results through Week 28 of the GO-ALIVE Study. ( 29419454 )
2018
12
The role of gut microbiota and IL-23/IL-17 pathway in ankylosing spondylitis immunopathogenesis: New insights and updates. ( 29409751 )
2018
13
Comorbidity, disability, and healthcare expenditure of ankylosing spondylitis in Korea: A population-based study. ( 29420599 )
2018
14
Immune cells involved in the pathogenesis of ankylosing spondylitis. ( 29428668 )
2018
15
Diffusion-weighted Imaging Is a Sensitive and Specific Magnetic Resonance Sequence in the Diagnosis of Ankylosing Spondylitis. ( 29449501 )
2018
16
TNF-I+ level affects etanercept clearance: TNF-I+ concentration as a new correction factor of allometric scaling to predict individual etanercept clearances in patients with ankylosing spondylitis. ( 29436715 )
2018
17
Atherogenic index of plasma: a useful marker for subclinical atherosclerosis in ankylosing spondylitis : AIP associate with cIMT in AS. ( 29435680 )
2018
18
Characterization of Patients With Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis in the US-Based Corrona Registry. ( 29409123 )
2018
19
Increased Levels of Oxidative Stress Markers, Soluble CD40 Ligand, and Carotid Intima-Media Thickness Reflect Acceleration of Atherosclerosis in Male Patients with Ankylosing Spondylitis in Active Phase and without the Classical Cardiovascular Risk Factors. ( 28883908 )
2017
20
Assessment of semaphorin 3A and its role in bone remodelling in a group of ankylosing spondylitis patients. ( 27782869 )
2017
21
A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis. ( 28148281 )
2017
22
Endothelial dysfunction is independent of inflammation and altered CCR7 T cell expression in patients with ankylosing spondylitis. ( 28421995 )
2017
23
ERAP1 association with ankylosing spondylitis is attributable to common genotypes rather than rare haplotype combinations. ( 28049827 )
2017
24
Epidural Haematoma Causing Paraplegia in a Patient with Ankylosing Spondylitis: A Case Report. ( 28824860 )
2017
25
Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors. ( 28880727 )
2017
26
Down-Regulation of lncRNA-AK001085 and its Influences on the Diagnosis of Ankylosing Spondylitis. ( 28042142 )
2017
27
Secular trends in sickness absence among Swedish patients with ankylosing spondylitis and psoriatic arthritis. ( 28879599 )
2017
28
Transpseudarthrosis Osteotomy with Interbody Fusion for Kyphotic Spinal Pseudarthrosis in Ankylosing Spondylitis by a Single Posterior Approach: A Retrospective Study and a Brief Relevant Literature Review. ( 28875150 )
2017
29
Assessment of Correlation between Intravoxel Incoherent Motion Diffusion Weighted MR Imaging and Dynamic Contrast-Enhanced MR Imaging of Sacroiliitis with Ankylosing Spondylitis. ( 29445743 )
2017
30
The reliability and validity of a Venezuelan version of the Bath Ankylosing Spondylitis Functional Index (BASFI) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). ( 28943073 )
2017
31
Evaluation of periostin and factors associated with new bone formation in ankylosing spondylitis: Periostin may be associated with the Wnt pathway. ( 28941122 )
2017
32
MEFV M694V mutation has a role in susceptibility to ankylosing spondylitis: A meta-analysis. ( 28800602 )
2017
33
Comparison of Outcomes of Total Hip Arthroplasty between Patients with Ankylosing Spondylitis and Avascular Necrosis of the Femoral Head. ( 28861192 )
2017
34
Relationship between the gut and the spine: a pilot study of first-degree relatives of patients with ankylosing spondylitis. ( 28879050 )
2017
35
Bioinformatics analysis of genetic variants of endoplasmic reticulum aminopeptidase 1 in ankylosing spondylitis. ( 28901420 )
2017
36
Association between use of disease-modifying antirheumatic drugs and diabetes in patients with ankylosing spondylitis, rheumatoid arthritis, or psoriasis/psoriatic arthritis: a nationwide, population-based cohort study of 84,989 patients. ( 28496328 )
2017
37
Position 97 of HLA-B, a residue implicated in pathogenesis of ankylosing spondylitis, plays a key role in cell surface free heavy chain expression. ( 27515058 )
2017
38
Increased expression of TIPE2 mRNA in PBMCs of patients with ankylosing spondylitis is negatively associated with the disease severity. ( 27816498 )
2017
39
Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2. ( 29435364 )
2017
40
Evaluation of auditory and cochlear functions in ankylosing spondylitis patients according to the site of involvement. ( 28889257 )
2017
41
Clinical efficacy of oral alendronate in ankylosing spondylitis: a randomised placebo-controlled trial. ( 28079501 )
2017
42
Mannose-binding lectin (MBL) deficiency and tuberculosis infection in patients with ankylosing spondylitis. ( 28879439 )
2017
43
A novel role for bone-derived cells in ankylosing spondylitis: Focus on IL-23. ( 28728847 )
2017
44
Ochronosis: a close mimic of ankylosing spondylitis. ( 29088416 )
2017
45
Evaluation of the internal oblique, external oblique, and transversus abdominalis muscles in patients with ankylosing spondylitis: an ultrasonographic study. ( 28891005 )
2017
46
Phlegmonous gastritis in an ankylosing spondylitis patient treated with infliximab. ( 28814069 )
2017
47
Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study. ( 28521824 )
2017
48
The potent suppressive effect of I^-d-mannuronic acid (M2000) on molecular expression of the TLR/NF-kB Signaling Pathway in ankylosing spondylitis patients. ( 28938189 )
2017
49
Developing a Risk-scoring Model for Ankylosing Spondylitis Based on a Combination of HLA-B27, Single-nucleotide Polymorphism, and Copy Number Variant Markers. ( 28042135 )
2017
50
Separate effects of the ankylosing spondylitis associated ERAP1 and ERAP2 aminopeptidases determine the influence of their combined phenotype on the HLA-B*27 peptidome. ( 28063628 )
2017

Variations for Spondyloarthropathy 1

ClinVar genetic disease variations for Spondyloarthropathy 1:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 HLA-B HLA-B, HLA-B27 undetermined variant risk factor

Expression for Spondyloarthropathy 1

Search GEO for disease gene expression data for Spondyloarthropathy 1.

Pathways for Spondyloarthropathy 1

Pathways related to Spondyloarthropathy 1 according to KEGG:

36
# Name Kegg Source Accession
1 Antigen processing and presentation hsa04612
2 Antirheumatics - DMARDs and biological agents hsamap07050

Pathways related to Spondyloarthropathy 1 according to GeneCards Suite gene sharing:

(show all 27)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.76 CD40LG CD79A CRP HLA-B IL17A IL1RN
2
Show member pathways
13.01 CD40LG HLA-B IL17A IL1RN MMP3 NOD2
3
Show member pathways
12.77 CD40LG HLA-B IL17A TAPBP TNF
4
Show member pathways
12.56 CD40LG CD79A TNF TNFRSF1A TNFRSF1B
5
Show member pathways
12.53 CD40LG TNF TNFRSF11B TNFRSF1A TNFRSF1B TNFSF11
6 12.16 CD40LG TNF TNFRSF1A TNFRSF1B TNFSF11
7 12.07 CD40LG CD79A IL17A IL1RN TNF TNFRSF1A
8 11.99 TNF TNFRSF11B TNFRSF1A TNFSF11
9 11.92 IL17A MMP3 TNF TNFRSF1B
10 11.82 CD40LG TNF TNFRSF1A TNFSF11
11 11.8 MMP3 NOD2 TNF TNFRSF1A TNFRSF1B
12 11.77 IL17A MMP3 TNF TNFSF11
13 11.64 TNF TNFRSF1A TNFRSF1B
14
Show member pathways
11.56 CD40LG MMP3 TNF TNFRSF1A
15 11.52 TNF TNFRSF1A TNFRSF1B
16
Show member pathways
11.52 CD40LG TNF TNFRSF1A TNFRSF1B TNFSF11
17
Show member pathways
11.47 TNF TNFRSF1A TNFRSF1B
18 11.42 IL1RN TNF TNFRSF1A TNFRSF1B
19 11.36 BGLAP TNF TNFRSF11B TNFSF11
20
Show member pathways
11.32 TNF TNFRSF1A TNFRSF1B
21 11.27 CD40LG TNFRSF1A TNFRSF1B
22 11.25 TNF TNFRSF1A TNFRSF1B
23 11.15 CD40LG IL17A TNF TNFSF11
24 11.09 NOD2 TNF TNFRSF1A
25
Show member pathways
11.01 CD40LG TNF TNFRSF11B TNFRSF1A TNFRSF1B TNFSF11
26 10.84 TNFRSF11B TNFSF11
27 10.8 BGLAP TNFRSF11B TNFSF11

GO Terms for Spondyloarthropathy 1

Cellular components related to Spondyloarthropathy 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.81 ANKH CD40LG CD79A HLA-B TNF TNFRSF11B
2 cell surface GO:0009986 9.8 CD40LG HLA-B NOD2 TNF TNFRSF1A
3 extracellular region GO:0005576 9.7 BGLAP CD40LG CRP IL17A IL1RN MMP3
4 external side of plasma membrane GO:0009897 9.67 CD40LG CD79A IL17A TNF
5 membrane raft GO:0045121 9.62 CD79A TNF TNFRSF1A TNFRSF1B
6 extracellular space GO:0005615 9.32 BGLAP CD40LG CRP IL17A IL1RN MMP3
7 plasma membrane GO:0005886 10.03 ANKH CD40LG CD79A HLA-B IL1RN MRAP

Biological processes related to Spondyloarthropathy 1 according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 regulation of cell proliferation GO:0042127 9.88 TNF TNFRSF11B TNFRSF1A TNFRSF1B
2 regulation of receptor activity GO:0010469 9.85 CD40LG IL17A IL1RN TNF TNFRSF11B TNFSF11
3 apoptotic signaling pathway GO:0097190 9.73 TNF TNFRSF11B TNFRSF1B
4 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.73 NOD2 TNF TNFRSF1A TNFSF11
5 positive regulation of JNK cascade GO:0046330 9.72 NOD2 TNF TNFSF11
6 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.71 CD40LG NOD2 TNF TNFSF11
7 response to glucocorticoid GO:0051384 9.7 BGLAP IL1RN TNF
8 positive regulation of MAP kinase activity GO:0043406 9.69 NOD2 TNF TNFSF11
9 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.65 TNF TNFRSF1A TNFRSF1B
10 tumor necrosis factor-mediated signaling pathway GO:0033209 9.63 CD40LG TNF TNFRSF11B TNFRSF1A TNFRSF1B TNFSF11
11 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.61 TNF TNFRSF1B
12 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.6 IL17A NOD2
13 response to inorganic substance GO:0010035 9.59 BGLAP TNFRSF11B
14 positive regulation of ceramide biosynthetic process GO:2000304 9.58 TNF TNFRSF1A
15 negative regulation of lipid storage GO:0010888 9.57 CRP TNF
16 inflammatory response GO:0006954 9.56 CD40LG CRP IL17A IL1RN TNF TNFRSF11B
17 death-inducing signaling complex assembly GO:0071550 9.54 TNF TNFRSF1A
18 positive regulation of osteoclast differentiation GO:0045672 9.5 IL17A TNF TNFSF11
19 regulation of establishment of endothelial barrier GO:1903140 9.49 TNF TNFRSF1A
20 regulation of immunoglobulin secretion GO:0051023 9.46 CD40LG TNF
21 regulation of osteoclast differentiation GO:0045670 9.43 BGLAP TNF TNFSF11
22 immune response GO:0006955 9.32 CD40LG HLA-B IL17A IL1RN TAPBP TNF

Molecular functions related to Spondyloarthropathy 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 tumor necrosis factor receptor binding GO:0005164 9.33 CD40LG TNF TNFSF11
2 tumor necrosis factor-activated receptor activity GO:0005031 9.13 TNFRSF11B TNFRSF1A TNFRSF1B
3 cytokine activity GO:0005125 9.1 CD40LG IL17A IL1RN TNF TNFRSF11B TNFSF11
4 protein binding GO:0005515 10.13 CD40LG CD79A CRP HLA-B IL17A IL1RN

Sources for Spondyloarthropathy 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....